Associated Papers
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M et al.
International Journal of Molecular Sciences, 2023
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Takayanagi D et al.
Cancers, 2021
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A et al.
International Journal of Molecular Sciences, 2019
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V et al.
Molecular Cancer, 2016
Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Lim SM et al.
Oncotarget, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Klughammer B et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
High-incidence of PTEN mutations in Chinese patients with primary small cell carcinoma of the esophagus.
Zhang Z et al.
Bmc Cancer, 2014
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer.
Kim S et al.
Plos One, 2014
Structural investigation of deleterious non-synonymous SNPs of EGFR gene.
Raghav D et al.
Interdisciplinary Sciences, Computational Life Sciences, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib.
Chen YM et al.
Oncology Letters, 2012
High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations.
Maeng CH et al.
Plos One, 2012
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
Deshpande V et al.
Bmc Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Co-conserved features associated with cis regulation of ErbB tyrosine kinases.
Mirza A et al.
Plos One, 2010
Profiling critical cancer gene mutations in clinical tumor samples.
MacConaill LE et al.
Plos One, 2009
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.
Chen Z et al.
Plos One, 2008
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Pedersen MW et al.
Ugeskrift for Laeger, 2006